Abstract:

Objective To investigate the effect of patient compliance on the efficacy of neoadjuvant therapyfor colorectal cancer based on the data from Database from Colorectal Cancer（DACCA）. Method The version ofDACCA was updated on Nov.14th，2019. We extracted the structured data of 328 patients with colorectal cancerwho received neoadjuvant therapy，and patients were divided into complete compliance group（n = 154）and partialcompliance group（n = 174）. A 1∶1 propensity score matching（PSM）was conducted according to basic data of thepatients，neoadjuvant therapy，patient compliance and other baseline data，and 88 cases were successfullymatched in each group. The efficacy of neoadjuvant therapy treatment was compared and analyzed between the twogroups. Results Before PSM，The compliance of the two groups of colorectal cancer patients was not associatedwith BMI，constitution，tumor location and clinical stage，（P > 0.05），but with age，gender and neoadjuvant therapytreatment cycle（P < 0.05）. Additionally，the degree of compliance positively correlated with neoadjuvant therapytreatment cycle（rs = 0.366，P < 0.001），but negatively with age（rs = -0.151，P = 0.006）. After PSM，there wasno statistically significant difference in clinical response degree between the two groups（P = 0.532），and in tumorregression grade（TRG）between the two groups（P = 0.612）. Conclusions For patients with colorectal cancerreceiving neoadjuvant therapy，patient compliance cannot yet be used as a powerful indicator for predicting or eval⁃uating the efficacy of neoadjuvant therapy.

Key words: compliance, colorectal cancer, neoadjuvant therapy, propensity score matching